> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Breakthrough Status for Preeclampsia Targeted Apheresis
- URL: https://www.fdaweb.com/breakthrough-status-for-preeclampsia-targeted-apheresis/
- Published: 2019-04-17T12:00:00.000Z
- Updated: 2026-09-15T01:20:57.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5143890

FDA has granted Advanced Prenatal Therapeutics a breakthrough device designation for its Targeted Apheresis Column for Preeclampsia (TAC-PE). The device is being designed to remove disease-causing factors from a mother’s blood. The company says it is intended to treat preeclampsia, a leading cause of prematurity and maternal/fetal death. “Now that we are preparing for initial clinical studies, we are very pleased that the breakthrough designation will help provide a clear and efficient pathway to market,” it says.